LAI
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics (NCT03376763) | Korea Otsuka Pharmaceutical Co., Ltd. | 2017-11-21 |
Track LAI automatically
Every clearance here is in the API, with alerts when new ones post.